Doxercalciferol
Vitamin D2 Analog — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
Also known as: hectorol
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Doxercalciferol is an ofp drug in the Vitamin D2 Analog class catalogued in DrugCentral. It was first approved by the FDA in 1999. DrugCentral lists 1 molecular target, including VDR. Recorded indications include Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis.
- Approval status: ofp (first approved 1999 by the FDA).
- Drug class: Vitamin D2 Analog.
- Molecular targets: VDR (1 listed in DrugCentral).
- Indications: Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis.
- ATC code: H05BX03 (Other anti-parathyroid agents).
- Molecular formula: C28H44O2; molecular weight 412.66 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis
Off-label uses (1)
- Hyperparathyroidism Secondary to Chronic Renal Failure
Contraindications (5)
- Disease of liver
- Hypercalcemia
- Hyperphosphatemia
- Hypervitaminosis D
- Hypoparathyroidism
Mechanism & targets
| Established pharmacologic class | Vitamin D2 Analog |
|---|
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Vitamin D3 receptor | VDR | agonist | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1999-06-09 | FDA | — | GENZYME CORP |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
H05BX03 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › CALCIUM HOMEOSTASIS › ANTI-PARATHYROID AGENTS › Other anti-parathyroid agents |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Drug hypersensitivity | 587.3 |
| Pruritus | 105.1 |
| Dyspnoea | 74.7 |
| Blood parathyroid hormone abnormal | 71.1 |
| Flushing | 56.2 |
| Unresponsive to stimuli | 51.9 |
| Feeling hot | 49.2 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Doxercalciferol is on its molecule page.
| Molecular formula | C28H44O2 |
|---|---|
| Molecular weight | 412.66 g/mol |
| CAS number | 54573-75-0 |
| InChIKey | HKXBNHCUPKIYDM-CGMHZMFXSA-N |
| PubChem CID | 5281107 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Doxercalciferol used for?
DrugCentral lists the following indications for Doxercalciferol: Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis.
How does Doxercalciferol work?
Its molecular targets in DrugCentral include VDR (agonist).
When was Doxercalciferol first approved?
Doxercalciferol was first approved by the FDA in 1999.
What drug class does Doxercalciferol belong to?
Doxercalciferol is in the Vitamin D2 Analog class.
What is the chemical formula of Doxercalciferol?
Doxercalciferol has the molecular formula C28H44O2 and a molecular weight of 412.66 g/mol.
Browse: all drugs starting with D · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 957 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200810 — compound record and bioactivity
- PubChem CID 5281107 — chemical identifiers
- DrugBank DB06410 — drug record
- FDA UNII 3DIZ9LF5Y9 — substance identity
- DailyMed: FDA labels for Doxercalciferol — current prescribing information (label search)
- UniProt P11473 (VDR) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.